Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
GlycoMimetics's peak revenue was $20.1M in 2015. The peak quarterly revenue was $20.0M in 2015(q2).
GlycoMimetics's revenue increased from $4.0m in 2013 to $10.0K currently. That's a -99.75% change in annual revenue.
| Fiscal year / year | GlycoMimetics revenue |
|---|---|
| 2013 | $4.0M |
| 2014 | $15.0M |
| 2015 | $20.1M |
| 2016 | $18,500 |
| 2020 | $10.2M |
| 2021 | $1.2M |
| 2022 | $75,000 |
| 2023 | $10,000 |
How accurately did GlycoMimetics' revenue projections match actual performance?
GlycoMimetics saw the greatest revenue growth in 2020, when revenue increased by 54,834.78%.
GlycoMimetics had the lowest revenue growth in 2016, when revenue changed by -99.91%.
| Year | GlycoMimetics growth |
|---|---|
| 2014 | 276%↑ |
| 2015 | 34%↑ |
| 2016 | -100%↓ |
| 2020 | 54835%↑ |
| 2021 | -89%↓ |
| 2022 | -94%↓ |
| 2023 | -87%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | - | $77,413 |
| 2014 | - | $15.0M | - | - |
| 2015 | - | $20.0M | - | $35,375 |
| 2016 | - | - | $18,500 | - |
| 2020 | $9.0M | - | $1.0M | $162,935 |
| 2021 | $1.1M | $142 | $86,560 | $17,625 |
| 2022 | - | $75,000 | - | - |
| 2023 | - | - | - | $10,012 |
Do you work at GlycoMimetics?
Is GlycoMimetics transparent about its revenue structure?
| CEO | Rachel K. King |
| Company Type | Public |
| Employees Number | 50 |
| Date Founded | 2003 |
| Headquarters | Rockville, Maryland |
| Number of Locations | 1 |
| Revenue | $10,000 |
| Net Income | -$46,688,802 |
| PE Ratio | -9.36 |
| Market Capitalization | $354.4M |
| Total Assets | $51,810,589 |
| Ticker | GLYC |
GlycoMimetics received early financing of $4.3M on 2003-05-22.
| Series | Round size | Date |
|---|---|---|
| Series A | $4.3M | 05/2003 |
| Series A | $5.1M | 08/2004 |
| Series B | $15.4M | 06/2006 |
| Series C | $38M | 12/2009 |
| Convertible Note | $39.0M | 10/2010 |
| Post Ipo Equity | $92.6M | 05/2017 |
| Investors | Security type |
|---|---|
| Novartis Venture Fund | Series A |
| Anthem Capital Management | Series A |
| New Enterprise Associates (NEA) | Series A |
| Alliance Ventures | Series A |
| Novartis Venture Fund | Series A |
| Anthem Capital Management | Series A |
| New Enterprise Associates (NEA) | Series A |
| Alliance Ventures | Series A |
| PTV Healthcare Capital | Series A |
| Maryland Department of Commerce | Series A |
| Novartis Venture Fund | Series B |
| Anthem Capital Management | Series B |
| New Enterprise Associates (NEA) | Series B |
| Alliance Ventures | Series B |
| PTV Healthcare Capital | Series B |
| Maryland Department of Commerce | Series B |
| Novartis Venture Fund | Series C |
| Anthem Capital Management | Series C |
| New Enterprise Associates (NEA) | Series C |
| Alliance Ventures | Series C |
| Sanofi Ventures | Series C |
Zippia gives an in-depth look into the details of GlycoMimetics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about GlycoMimetics. The employee data is based on information from people who have self-reported their past or current employments at GlycoMimetics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by GlycoMimetics. The data presented on this page does not represent the view of GlycoMimetics and its employees or that of Zippia.
GlycoMimetics may also be known as or be related to GLYCOMIMETICS INC, GlycoMimetics, GlycoMimetics Inc, GlycoMimetics, Inc. and Glycomimetics.